1-12 of 12
Karen Rodriguez Lorenc
Close
Sort by
Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Sundar Jagannath, Joshua Richter, Madhav V. Dhodapkar, James E. Hoffman, Hans C. Lee, Attaya Suvannasankha, Mansi R. Shah, Suzanne Lentzsch, Jeffrey A. Zonder, Rachid Baz, Joseph J. Maly, Swathi Namburi, Ka Lung Wu, Matthew Pianko, Jing Christine Ye, Rebecca Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquín Martínez Lopez, Michelle DeVeaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn S. Kroog, Yariv Houvras, Naresh Bumma
Journal: Blood
Blood (2023) 142 (Supplement 1): 4746.
https://doi.org/10.1182/blood-2023-177968
Published: 2023
Journal Articles

Incidence of Second Primary Malignancies in Medicare-Insured Patients in the US with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Sikander Ailawadhi, Thomas Delea, Aaron Moynahan, Wenzhen Ge, Christian Hampp, Alexi Archambault, Ning Wu, Karen Rodriguez Lorenc, Irene Noguera-Troise, Glenn S. Kroog, Yariv Houvras, Qiufei Ma
Journal: Blood
Blood (2023) 142 (Supplement 1): 912.
https://doi.org/10.1182/blood-2023-188562
Published: 2023
Journal Articles

Trial in Progress: A Phase 2 Study of Linvoseltamab for the Treatment of High-Risk Smoldering Multiple Myeloma (LINKER-SMM1)

Paula Rodriguez Otero, Maria-Victoria Mateos, Oluwaseun Aina, Arijit Sinha, Andrew J Steele, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn M Sarkaria, Jesus San Miguel
Journal: Blood
Blood (2023) 142 (Supplement 1): 3393.
https://doi.org/10.1182/blood-2023-179356
Published: 2023
Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

James E. Hoffman, Naresh Bumma, Joshua Richter, Madhav V. Dhodapkar, Hans C. Lee, Attaya Suvannasankha, Christiane A. Houde, Joseph J. Maly, Mansi R. Shah, Rachid Baz, Swathi Namburi, Ka Lung Wu, Matthew Pianko, Jing Christine Ye, Suzanne Lentzsch, Rebecca Silbermann, Chang-Ki Min, Marie-Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquín Martínez Lopez, Michelle DeVeaux, Cristina Ivanescu, Karen Rodriguez Lorenc, Glenn S. Kroog, Yariv Houvras, Timothy J. Inocencio, Lei Chi, James Harnett, Qiufei Ma, Sundar Jagannath
Journal: Blood
Blood (2023) 142 (Supplement 1): 3359.
https://doi.org/10.1182/blood-2023-179170
Published: 2023
Journal Articles

Real-World Study of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Medicare Patients in the United States

Thomas Delea, Aaron Moynahan, Wenzhen Ge, Xue Song, Glenn S. Kroog, Irene Noguera-Troise, Karen Rodriguez Lorenc, Qiufei Ma
Journal: Blood
Blood (2023) 142 (Supplement 1): 3773.
https://doi.org/10.1182/blood-2023-188591
Published: 2023
Journal Articles

Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States

Qiufei Ma, Xue Song, Thomas E. Delea, Glenn S. Kroog, Wenzhen Ge, Lei Chi, Aaron Moynahan, Derek Weycker, Karen Rodriguez Lorenc
Journal: Blood
Blood (2022) 140 (Supplement 1): 5298–5300.
https://doi.org/10.1182/blood-2022-158142
Published: 2022
Journal Articles

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Paula Rodríguez Otero, Nisha S. Joseph, Shaji K Kumar, Hans C. Lee, Xavier Leleu, Salomon Manier, Meletios A. Dimopoulos, María Victoria Mateos, Albert Oriol, Naresh Bumma, Weiying Gong, Pourab Roy, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn M. Sarkaria
Journal: Blood
Blood (2022) 140 (Supplement 1): 4444–4446.
https://doi.org/10.1182/blood-2022-157713
Published: 2022
Journal Articles

Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020

Sikander Ailawadhi, Qiufei Ma, Jessica J. Jalbert, Mo Zhou, Zheng-Yi Zhou, Nathaniel Downes, Adina Zhang, Lei Chi, Christian Hampp, Xue Song, Irene Noguera-Troise, Jonathan Weyne, Glenn S. Kroog, Karen Rodriguez Lorenc
Journal: Blood
Blood (2022) 140 (Supplement 1): 5272–5273.
https://doi.org/10.1182/blood-2022-158401
Published: 2022
Journal Articles

Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Wenzhen Ge, Alexi Archambault, Thomas E. Delea, Karen Rodriguez Lorenc, James Harnett, Aaron Moynahan, Derek Weycker, Yariv Houvras, Glenn S. Kroog, Ning Wu, Christian Hampp, Qiufei Ma
Journal: Blood
Blood (2022) 140 (Supplement 1): 10897–10899.
https://doi.org/10.1182/blood-2022-158013
Published: 2022
Journal Articles

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Naresh Bumma, Joshua Richter, Jason Brayer, Jeffrey A. Zonder, Madhav Dhodapkar, Mansi R. Shah, James E. Hoffman, Raya Mawad, Joseph J. Maly, Suzanne Lentzsch, Attaya Suvannasankha, Pourab Roy, Jyotirmoy Dey, Dhruti Chokshi, Anita Boyapati, Jenn Visich, Yariv Houvras, Karen Rodriguez Lorenc, Glenn S. Kroog, Sundar Jagannath
Journal: Blood
Blood (2022) 140 (Supplement 1): 10140–10141.
https://doi.org/10.1182/blood-2022-159969
Published: 2022
Journal Articles

Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma

Christopher J. Ferreri, Steven E. Quatela, Sean Aina, Pourab Roy, Anita Boyapati, Karen Rodriguez Lorenc, Glenn S. Kroog, Robert Z. Orlowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 10129–10130.
https://doi.org/10.1182/blood-2022-158396
Published: 2022
Journal Articles

Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Jeffrey A. Zonder, Joshua Richter, Naresh Bumma, Jason Brayer, James E Hoffman, William I. Bensinger, Ka Lung Wu, Linzhi Xu, Dhruti Chokshi, Anita Boyapati, Manish Sharma, Karen Rodriguez Lorenc, Glenn S Kroog, Madhav V Dhodapkar, Suzanne Lentzsch, Dennis Cooper, Sundar Jagannath
Journal: Blood
Blood (2021) 138 (Supplement 1): 160.
https://doi.org/10.1182/blood-2021-144921
Published: 2021